Quick Takeaways
- Inscobee Inc. filed SCHEDULE 13D for Apimeds Pharmaceuticals US, Inc. Common Stock (APUS).
- Disclosed ownership: 38%.
- Date of event: 12 May 2025.
Inscobee Inc. - 12 May 2025 SCHEDULE 13D Report for Apimeds Pharmaceuticals US, Inc. Common Stock (APUS)
- Filing Manager
- Inscobee Inc.
- Reporting Manager
- Apimeds Inc.
- Symbol
- APUS
- Shares outstanding
- 11,577,066 shares
- Disclosed Ownership
- 4,387,708 shares
- Ownership
- 38%
- Form type
- SCHEDULE 13D
- Filing time
- 19 May 2025, 21:29:56 UTC
- Date of event
- 12 May 2025
- Next filing
- 26 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Inscobee Inc. disclosed 38% ownership in Apimeds Pharmaceuticals US, Inc. Common Stock (APUS) on 12 May 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 19 May 2025, 21:29.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Inscobee Inc. | 18% | 2,028,657 | 2,028,657 | 0 | /s/ Jakap Koo | Jakap Koo, Chief Executive Officer | 0002057997 |
| Apimeds Inc. | 38% | 4,387,708 | 4,387,708 | 0 | /s/ Jakap Koo | Jakap Koo, Chief Executive Officer |